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Thispaperpresentsasingle-institutionexperienceregardingtheclinicopathologicfeaturesandtreatmentstrategiesusedinuterine
clear cell cancer (UCC), a rare, aggressive histologic subtype of uterine cancer with poor prognosis and discusses parameters
associated with progression-free survival (PFS) and overall survival (OS). A retrospective chart review was performed on all
patients(n = 80)diagnosedwithUCCandtreatedbetween1994and2009atasingleacademicinstitution.Dataondemographics,
FIGOstage,treatmentregimens,andrecurrenceswerecollected. Patientswithearly-stageUCChadanexcellent survivalregardless
of adjuvant therapy. Advanced-stage patients had a worse survival. Vaginal apex brachytherapy was associated with an increased
OS (P = 0.02) but not PFS (P = 0.10). The use of platinum-based chemotherapy in combination with vaginal apex brachytherapy
did not signiﬁcantly improve survival. Innovative therapies still need to be identiﬁed for this uncommon uterine cancer.
1.Introduction
Endometrial cancer is the most common gynecologic cancer
in the United States, with 43,470 new cases and 7,950
deaths estimated in 2010 [1]. The incidence of endometrial
cancer is greater than that of all other female genital tract
malignancies combined [1]. Clear cell carcinoma of the
uterine corpus (UCC), a rare subtype accounting for 1–
6% of uterine cancers, is characterized histologically by
the clearing of tumor cell cytoplasm [2–5]. Patients with
UCC are more likely to present with higher-stage disease
than those with endometrioid histology, and clear cell
histology has been considered a poor prognostic factor
[2, 6]. Comprehensive surgical staging is recommended in
women with UCC, given the high error rate with clinical
staging [7]. Aggressive, multimodal treatment (including
surgery, chemotherapy, and/or radiation therapy) is usually
recommended as compared to type I endometrial cancers.
Due to the rarity of UCC, there are no prospective studies
evaluating these treatments solely in women with UCC [4].
Compared with endometrioid and serous carcinomas,
little is known about the molecular pathways and immuno-
phenotypic proﬁle involved in UCC. Studies have conﬁrmed
that UCC is genetically distinct from endometrioid cancer
[8]. Clear cell tumors show similar gene expression proﬁles
regardless of organ of origin [8, 9]. Type II endometrial
tumors tend to display p53 mutations, compared to Type I
cancers [2].
The goal of this paper was to present the clinicopatho-
logic features and treatment strategies used in UCC and
determine what parameters are associated with progression-
free survival (PFS) and overall survival (OS).
2.MaterialsandMethods
A retrospective chart review was performed on all patients
withthediagnosisofUCCfrom1994–2009whoweretreated2 Journal of Oncology
at the Yale-New Haven Hospital (YNHH). A YNHH Tumor
Registry search under the search terms “endometrial cancer”
and “clear cell” identiﬁed 80 patients with UCC.
Medical charts, including admission and discharge notes,
as well as surgical pathology reports and treatment records
(chemotherapy and radiation) were reviewed, and epidemi-
ological data (age at diagnosis, ethnicity, gravity, and parity),
clinical data (past medical history, menstrual history, smok-
ing history, hormone or tamoxifen use, personal or family
history of other malignancies, body mass index (BMI)),
and pathologic and histological data (stage, lymphovascular
space involvement, positive pelvic washings, involvement of
polyps, lymph node metastases, depth of myometrial inva-
sion) as well as survival data (disease-free and overall sur-
vival) were extracted. All pathology and cytology specimens
had been previously reviewed by gynecologic pathologists
at YNHH. Seventy-six patients were staged using the Inter-
national Federation of Gynecology and Obstetrics (FIGO)
1988 operative staging system for endometrial cancer. The
remaining 4 patients had palliative treatment only.
Long-term follow-up data were censored at date of last
followup. PFS was calculated from date of diagnosis until
date of recurrence, death, or last followup. OS was calculated
from date of diagnosis until death or date of last followup.
Cox proportional hazards multivariable models and Kaplan-
Meier test were used for survival analysis. A P<0.05 was
considered statistically signiﬁcant. Statistical analyses were
performed using SAS 9.2 (SAS Institute, Cary, NC). This
researchwasapproved by the Human Investigation Commit-
teeatYaleUniversitySchoolofMedicine(HIC#0804003674).
3. Results
A total of 80 patients with UCC were identiﬁed. Their
mean age at diagnosis was 67 years (range 43 to 91 years)
(Table 1). Most patients were Caucasian (86.3%, n = 69).
Medical comorbidities at the time of diagnosis included
hypertension(57.5%),diabetes(27.5%),andcoronaryartery
disease (17.5%). Parity was known for 67 patients (83.8%),
and of these patients, 95.5% were parous. Eighteen patients
(22.5%) had a history of other malignancies. Seven patients
(8.8%) had previously been diagnosed with breast cancer
and 5 patients (6.3%) with colon cancer. A family history
of malignancy in a ﬁrst-degree relative was found in 34
patients (42.5%), with colon cancer being the most common
diagnosis (12.5%, n = 10). Other malignancies in family
histories included breast (10%, n = 8), uterus (7.5%, n = 6),
ovary, prostate, lung, stomach, and brain tumor.
Twelve of the 80 patients (15%) had used hormone-
replacement therapy for any duration of time. Eleven
patients (13.8%) had a history of oral contraceptive use,
and 5 (6.3%) had used tamoxifen. The majority of patients
(62.5%,n = 50)hadaBMIthatclassiﬁedthemasoverweight
or obese. Twenty-ﬁve patients (31.3%) reported that they
were past or current smokers.
Forty of the 80 patients (50%) had Stage I disease, 13
(16.3%) had Stage II, 12 (15%) had Stage III, and 15 (18.8%)
had Stage IV disease (Table 2). The majority of patients
Table 1: Patient demographics.
Characteristic Number of patients Percent
Age at diagnosis (years)
40–49 5 6.3
50–59 13 16.3
60–69 30 37.5
70–79 16 20.0
80–89 15 18.8
≥90 1 1.3
Race
Caucasian 69 86.3
African-American 4 5.0
Unknown 7 8.8
Positive medical history
Obesity 50 62.5
Hypertension 46 57.5
Diabetes 22 27.5
Coronary artery disease 14 17.5
Breast cancer 7 8.8
Colon cancer 5 6.3
Other malignancy 6 7.5
Past or current tobacco use 25 31.3
Medication use (past or current)
Hormone replacement therapy 12 15.0
Oral contraceptives 11 13.8
Tamoxifen 5 6.3
(72.5%, n = 58) had clear cell histology in combination with
serous and/or endometrioid histology. All patients with an
endometrioid component had FIGO grade 2 or 3 disease.
Nineteen patients (23.8%) had positive peritoneal wash-
ings (Table 2). Eighteen patients (22.5%) had metastases
documented at the time of diagnosis. Twenty-ﬁve patients
(31.3%) had a focal (<10%) clear cell component within the
endometrium. Twenty-two were pure clear cell tumors, and
33 were of mixed histology (Table 2). Thirty-three patients
(41.3%) had lymphovascular space invasion. Forty-ﬁve
patients (56.3%) had lower uterine segment involvement,
25 patients (31.3%) had endocervical involvement, and 10
patients(12.5%)hadomentalinvolvement.Thirteenpatients
(16.3%) had positive lymph nodes.
Radiation was part of the adjuvant treatment for 63
patients (78.8%) (Table 3). All but one of these patients
received vaginal brachytherapy (remote after loading 192Ir
source to a total dose of 21 Gy in 3 fractions or 14 Gy in 2
fractions at 0.5cm from the vaginal mucosa). One patient
was treated only with external beam radiation therapy
(EBRT). Five patients received EBRT along with vaginal
brachytherapy. One patient received vaginal brachytherapy
and whole abdomen radiation treatment with a pelvic boost.
Two patients were treated with radiation therapy only at
the time of recurrence. Fifty-three patients (66.3%) received
chemotherapy (Table 3). Of these, 84.9% (n = 45) were
treated with a platinum-based regimen, 35 (66%) of whom
received carboplatin (AUC = 6) and paclitaxel (175mg/m2)Journal of Oncology 3
Table 2: Histopathologic ﬁndings.
Number of
patients Percent
Stage (FIGOa 1988)
I 40 50.0
II 13 16.3
III 12 15.0
IV 15 18.8
Histology
Pure clear cell 22 27.5
Clear cell + serous ± endometrioid 36 45.0
Clear cell + endometrioid (no serous
component) 22 27.5
Washings
Positive 17 21.3
Negative 61 76.3
Not done 2 2.5
Lymph nodes
Positive 13 16.3
Negative 67 83.8
aInternational Federation of Gynecology and Obstetrics.
Table 3: Adjuvant treatment.
Number
of
patients
Percent
Radiation 63 78.8
VBa only 56 70.0
VB + EBRTb 56 . 2 5
EBRT only 1 1.25
VB + WARTc 11 . 2 5
Chemotherapy 53 66.3
Carboplatin & Paclitaxel 35 43.75
Cyclophosphamide, Adriamycin, &
Cisplatin 10 12.5
Other (inc. topotecan, weekly paclitaxel) 8 10.0
aVB: vaginal brachytherapy; bEBRT: external beam radiation therapy;
cWART: whole abdomen radiation therapy.
intravenously weekly for 6 cycles. Other regimens used were
adriamycin/cyclophosphamide/cisplatin (CAP), topotecan,
and weekly paclitaxel. Forty-one of the 53 patients who
received chemotherapy also had vaginal brachytherapy.
MedianfollowupforPFSandOSwere38months(range:
0 to 175) and 54 months (range: 0 to 250), respectively. For
patients with Stage I disease, median followup for PFS was
65.5 months (range: 0 to 160) and for OS was 69.5 months
(range:5to250).InStageIIdisease,medianfollowupforPFS
was 30 months (range: 0 to 142) and for OS was 44 months
(range: 10 to 142), and patients with Stage III cancers had
median followup for PFS of 15 months (range: 1 to 95) and
forOSof20.5months(range:1to95).PatientswithStageIV
disease had a median followup for PFS of 10 months (range:
Table 4: Patient outcomes.
Number of
patients Percent
Alive no evidence of disease 43 53.8
Alive with disease 5 6.3
Dead of disease 21 26.3
Dead no evidence of disease 10 12.3
Lost to follow-up (disease status
unknown) 11 . 3
0 to 175) and median followup for OS of 27 months (range:
0 to 175 months). At the end of this study, 48 patients (60%)
were alive (5 [6.3%] with disease) and 32 patients (40%)
had died (Table 4). A total of 17 patients (21.3%) recurred
with 4 still alive and 13 succumbing to their disease. PFS
was not signiﬁcantly diﬀerent between patients with early-
stage (Stages I&II) disease and late-stage (Stages III&IV)
disease(Figure 1(a);P = 0.377).However,OSwassigniﬁcant
between these two groups with early-stage disease having
a median OS of 135 months (95% CI: 84–250) compared
to those with late-stage disease of 65 months (Figure 1(b);
P = 0.008).
Apatient’shistology(pureclearcell,clearcellplusserous,
or clear cell plus endometrioid) did not have a signiﬁcant
relationship with PFS or OS. In patients with pure clear cell
histology (n = 2 2 ) ,m e d i a nP F Sw a s3 0m o n t h s( r a n g e :0
to 134), and median OS was 43.5 months (range: 1 to 134),
while patients with any serous component (n = 36) had a
median PFS of 32 months (range: 0 to 175) and OS of 47
months (range: 0 to 250). Patients with mixed endometrioid
and clear cell histology (n = 22) had the best survival, with
a median PFS of 61.5 months (range: 0 to 160) and OS of
65.5 months (range: 5 to 237), although this did not reach
statistical signiﬁcance when compared with other histologic
subtypes(P = 0.21).Lymphovascularspaceinvasionalsodid
not correlate clinically with survival.
Operative notes were available for 72 patients. Of these
patients, all but 4 were debulked to no residual disease
(n = 65) or residual disease of less than 1cm (n = 3). All
of the patients with residual disease had Stage IV disease.
Their progression-free and overall survivals ranged from 1
to 70 months. When considering all patients, the presence of
residual disease had a signiﬁcant impact on OS (P<0.0001)
but not on PFS (P = 0.1). The median overall survival in
patients with residual disease, even if optimally debulked to
lessthan1cmofdisease,was17.5monthsversus135months
in those patients with no residual disease.
There was a signiﬁcant relationship between age at
diagnosisandOS(P<0.001;hazardratio1.07;95%CI1.03–
1.12), independent of FIGO stage. Increased age contributed
to shorter overall survival. However, there was no signiﬁcant
relationship between age at diagnosis and PFS (P = 0.23;
95% CI 0.98–1.09).
In univariate analysis, vaginal brachytherapy, whether
aloneorin combinationwith otherradiation therapy, hadan
impact on OS (median survival with radiation: 140 months
versus without radiation: 50 months; P = 0.02), but not on4 Journal of Oncology
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Figure 1: (a) Kaplan-Meier survival curve showing Progression-
Free survival in early-stage versus late-stage disease in clear cell
endometrial cancer, (b) Kaplan-Meier survival curve showing
overall survival in early-stage versus late-stage disease in clear cell
endometrial cancer.
PFS (P = 0.10). This association was not noted after testing
in a multiple regression model. Adjuvant chemotherapy had
no signiﬁcant impact on OS (P = 0.26) or PFS (P =
0.27). When patients treated with vaginal brachytherapy
plus carboplatin and paclitaxel (n = 28) were compared
to patients who were not treated with this regimen, no
signiﬁcant diﬀerence was seen in OS or PFS (P = 0.82 and
P = 0.39, resp.).
4. Discussion
Given the rarity of the diagnosis of UCC, meaningful data
is lacking in the form of prospective randomized controlled
trials. Historically, Abeler and Kjorstad published a chart
review of 97 patients with UCC. Although the patients were
treated based on diﬀerent protocols, they found a 5-year
survival rate of 42.3% and 10-year survival at 30.9% [10].
No patient with Stage III or IV survived 5 years. Age did not
correlate with survival, implying that UCC histology was the
most important prognostic factor. Recently, better survival
rates of 79% 5-year survival for early disease and 21% for
advanced disease have been reported [7].
Fifty percent of our patients presented with Stage I
disease, which is higher than usual as most patients present
with metastatic disease [5]. This diﬀerence may be because
the majority of our patients had mixed histology (clear cell
plus serous and/or endometrioid) and not pure clear cell
carcinoma. Our ﬁndings were consistent with a previous
publication reporting LVI to have no eﬀect on survival in
endometrial cancer [11].
To our knowledge, there are no published studies on
the impact of residual disease on survival in UCC. Previous
studies have demonstrated a signiﬁcant survival beneﬁt with
optimal cytoreduction at primary surgery in uterine serous
carcinoma [12]. When attempting to look at the role of
optimal debulking in survival of UCC patients, only 4
patients (5%) in our present study had residual disease of
greater than 1 centimeter. While no conclusions can be
drawn regarding clear cell histology because of the small
number of advanced stage patients in this study, residual
disease may be an important factor to consider in future
research on survival in UCC patients.
While surgical staging (total hysterectomy, bilateral
salpingo-oophorectomy, pelvic and para-aortic lymphaden-
ectomy, omentectomy, peritoneal cavity evaluation with
washing, smears, and biopsies of suspicious-looking areas)
and optimal cytoreduction are the standard of care in
patients with UCC, optimal postoperative management is
far from being deﬁned. Treatment strategies vary at diﬀerent
stages.GiventhesmallnumberofwomenaﬀectedwithUCC,
factors associated with improved survival are diﬃcult to
discern. The Society of Gynecologic Oncology reported that
although adjuvant radiation is commonly oﬀered to patients
with all stages of UCC, no studies have demonstrated
improvements in OS, largely because of lack of power
[4]. Studies looking exclusively at UCC are limited [2].
Radiotherapy may be justiﬁed given that it may provide
improved local control. The present study hypothesizes that
there may be an impact on OS when patients received
v a g i n a la p e xb r a c h y t h e r a p y .H o w e v e r ,m o r ed a t ai sn e e d e d
to conﬁrm this observation.
No studies have been performed regarding adjuvant
chemotherapy in an exclusively UCC population [4, 5]. Sev-
eral studies examined the role of postoperative chemother-
apy in endometrial cancer. The Gynecologic Oncology
Group (GOG) 139 trial prospectively evaluated the largest
population of pure UCC patients (n = 44) for chemotherapy
response, although UCC patients only comprised 3.7%
of the total study population [13]. Clear cell histology
was a negative predictor for PFS and OS compared to
other histologic subtypes. Carboplatin and paclitaxel have
some eﬃcacy in women with UCC with acceptable toxicity
[14]. Although other chemotherapeutic regimens have been
examined, their eﬃcacy in the UCC subset of patients has
yet to be established [15]. A prospective cohort study of 22
patients with Stage I UCC and uterine serous carcinoma
concluded that adjuvant therapy may not be necessary in
early-stage patients after surgical staging [16]. Given the data
available, the authors believe it is reasonable to oﬀer all
patientswithUCCadjuvantchemotherapy,althoughthebestJournal of Oncology 5
therapeuticregimenanditstruebeneﬁtinStageIpatientsare
still up for discussion.
The potential association of endometrial cancer with
other malignancies, particularly carcinomas of the breast
and colon, has been investigated previously [17]. A study
comparing the rate of breast cancer in patients with uterine
serous cancer and that in patients with endometrioid
endometrial cancer demonstrated that 19.4% of serous
patients had a history of breast cancer compared to 3%
of those with endometrioid histology [18]. In our study,
8.8% of our patients had a personal history of breast cancer.
This disparity in breast cancer rates between uterine serous
cancers and UCC may be due to diﬀerences in breast cancer
treatment and rates of tamoxifen use or more likely, due
to the fact that many of our patients had mixed histology.
Women with Lynch syndrome have a 20–60% lifetime risk of
developing endometrial cancer [19]. In fact, many women
with Lynch syndrome present with endometrial cancer as
their ﬁrst malignancy [20]. There is a higher incidence of
nonendometrioid endometrial cancer in patients with Lynch
Syndrome(43%)thaninthosewithsporadicuterinetumors,
despite younger mean age at diagnosis. In one recent study
of patients with endometrial cancer and Lynch syndrome,
the authors reported that 21% of the patients had clear cell
cancer [19]. Five patients (6.3%) in our study had a personal
history of colon cancer, one of whom had a sister with
colon cancer. An additional ﬁve patients had a ﬁrst-degree
relative with colon cancer, without a personal history of
gastrointestinal malignancy. Providers should keep in mind
that patients diagnosed with UCC (particularly at a younger
age) may carry the Lynch syndrome mutation.
5. Conclusions
This retrospective, single-institution report of uterine clear
cell cancer demonstrates that most patients with UCC
have clear cell histology in combination with serous and/or
endometrioid histology. In our present study, we show
that age and early-stage versus late-stage disease have a
signiﬁcant impact on overall survival. Of particular interest,
vaginal brachytherapy also had an impact on overall survival
regardless of other aspects of a patient’s treatment. When
comparing this data with data from patients with uterine
serous cancer from the same institution, there does not seem
to be a great diﬀerence in recurrence rates between clear cell
and serous histologies. In a study by Kelly et al., 28% of Stage
I serous cancers recurred, and in our study 20% of Stage
I UCC patients recurred [21]. As with all research on this
aggressive histologic subtype of endometrial cancer, our data
is limited by small sample size. However, these results may
help guide future prospective research from which we draw
moreconcreteconclusionsregardingtreatmentandfollowup
of patients with UCC.
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